Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna VOC testing Coverage Policy Update | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0717

    Analysis of Volatile Organic Compounds

    Customize your policy alerts

    Sign up for Aetna Policy 0717 alerts

    Get alerted when Policy 0717 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the coverage stance for tests that analyze volatile organic compounds (VOCs) in biologic specimens (e.g., urine, blood, breath) for diagnosis, screening, or monitoring of disease. It affects providers and laboratories submitting claims to Aetna for VOC analysis.

    Policy Summary
    PayerAetna
    PolicyAnalysis of Volatile Organic Compounds
    Policy CodePolicy 0717
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateOct 4, 2005
    Last ReviewOct 3, 2023
    Next Review DateAug 8, 2024
    Key ActionDo not submit claims for VOC analysis for the listed indications because tests are considered experimental/investigational without adequate clinical validation.
    SourceLink
    multipleExperimental indications
    1,038OMA study samples
    0.87CRC pooled AUC
    0.96Pediatric IBD AUC
    75+References cited

    Coverage Criteria

    Experimental and Investigational

    Not covered (considered experimental and investigational) for the following indications because clinical effectiveness has not been established:

    Experimental/Investigational Indications: Analysis of volatile organic compounds is considered experimental and investigational for the following indications: detection of bacteriuria; detection of bronchiolitis obliterans syndrome in lung transplant recipients; detection of cancer (including bladder, breast, colorectal, esophagogastric, gallbladder, gastric, hepatobiliary, leukemia/lymphoma, lung and pleural, pancreatic, and renal cancers); diagnosis and monitoring of pleural mesothelioma; diagnosis and monitoring of sarcoidosis; diagnosis of alcoholic hepatitis; diagnosis of autism spectrum disorders; diagnosis of celiac disease; diagnosis of idiopathic membranous nephropathy; diagnosis of infection; diagnosis of inflammatory bowel disease; diagnosis of juvenile idiopathic arthritis; diagnosis of lung disease (e.g., asthma); diagnosis of neuromuscular disease (e.g., amyotrophic lateral sclerosis); diagnosis of non-alcoholic fatty liver disease; diagnosis of non-healing surgical wounds; diagnosis of obstructive sleep apnea; diagnosis of oral candidiasis; diagnosis of pneumonia; diagnosis of tuberculosis; differential diagnosis of breast diseases (e.g., breast cancer, cyclomastopathy, mammary gland fibroma); prediction of asthma exacerbations; prediction of development of childhood obesity; prediction of development of necrotizing enterocolitis; screening for COVID-19; use as biomarkers of chronic obstructive pulmonary disease; and use as markers for monitoring hemodialysis efficiency.

    List not exhaustive

    Conditional coverage requirements

    Policy Summary
    PayerAetna
    PolicyAnalysis of Volatile Organic Compounds
    Policy CodePolicy 0717
    Change TypeNo material clinical or coverage changes in this revision
    Effective DateOct 4, 2005
    Last ReviewOct 3, 2023
    Next Review DateAug 8, 2024
    Key ActionDo not submit claims for VOC analysis for the listed indications because tests are considered experimental/investigational without adequate clinical validation.
    SourceLink
    On This Page
    Coverage CriteriaCovered or Investigational IndicationsNot CoveredCodingProvider Actions and Operational NotesOrdering RequirementsFrequency LimitsBackground and DefinitionsResearch Evidence HighlightsRevision History

    Coverage stance is conditional on validation and standardization

    Validation and standardization required

    • 1.: Assay method and sample collection are standardized and documented (including sample medium and collection/handling procedures).
    • 2.: Diagnostic performance is validated in independent external cohorts with appropriate reference standards (e.g., culture for UTI, colonoscopy for CRC).
    • 3.: Prospective studies demonstrate clinical utility and impact on patient outcomes, including assessment of reproducibility across centers and analytic platforms.

    Evidence summaries (informational, not coverage rules)

    Summary of evidence-based considerations (informational):

    CRC urinary VOC evidence: Urinary VOCs have discriminated colorectal cancer from controls in multiple studies and meta-analyses; pooled chemical-fingerprint sensitivity ~84% and specificity ~70%, and pooled AUC ~0.87. However, studies varied in methodology and quality; recommended standardized sample collection (sealed containers, immediate freezing, analysis within specified intervals), analytic strategy, multicenter validation, and colonoscopy reference standards are needed before clinical implementation.
    TB eNose evidence: Portable electronic-nose devices have shown high specificity and negative predictive value in small or low-prevalence cohorts, but lack of culture-confirmed TB cases and small sample sizes prevent reliable sensitivity estimates; larger studies with adequate case prevalence are required.
    COVID-19 breath VOC evidence: Breath-VOC approaches and rapid point-of-care platforms (e.g., GC-IMS with ML models, FTIR/AI systems) have reported high discrimination in limited cohorts and rapid test times (minutes), but heterogeneity in populations, sampling, platforms, and lack of standardized biomarkers or cutoffs limit generalizability and require further validation.

    This policy explicitly lists a wide range of clinical indications for which analysis of volatile organic compounds (VOCs) is considered experimental and investigational because clinical effectiveness has not been established. Examples include detection of bacteriuria; detection of bronchiolitis obliterans syndrome after lung transplant; detection, diagnosis, or monitoring of multiple cancers (bladder, breast, colorectal, esophagogastric, gallbladder, gastric, hepatobiliary, lung, pancreatic, renal, pleural malignancies); diagnosis and monitoring of pleural mesothelioma and sarcoidosis; several metabolic, inflammatory, infectious, pediatric and neurologic conditions (e.g., alcoholic hepatitis, autism spectrum disorders, celiac disease, idiopathic membranous nephropathy, inflammatory bowel disease, juvenile idiopathic arthritis, asthma, amyotrophic lateral sclerosis); prediction of asthma exacerbations, childhood obesity, or necrotizing enterocolitis; screening for COVID‑19; use as biomarkers for COPD; and monitoring hemodialysis efficiency. The list is not exhaustive and the policy treats these uses as investigational and excluded from routine coverage.

    Exhaled VOCs and biomarkers in exhaled breath condensate are described in the policy as a research tool for pediatric respiratory diseases and are not validated for routine clinical use. The document highlights large literature searches with only a small fraction of original pediatric VOC studies and emphasizes lack of longitudinal data and external validation as barriers to clinical implementation.

    The policy notes that many published studies of VOCs are observational, include small sample sizes, and are heterogeneous in design and sampling media. Systematic reviews cited in the policy report selection biases, inadequate reporting of clinical parameters (including cancer stage), and substantial methodological variation that limit the strength and generalizability of the evidence.

    VOC tests that lack standardized collection and analytic methods, absence of external validation, or are limited to small pilot/case‑control studies are identified in the policy as not ready for routine clinical implementation and therefore unsupported for coverage until standardized and externally validated.

    The policy emphasizes that variable sample collection protocols and analytic approaches—such as differences in sample containers, handling (e.g., immediate freezing for urine), timing, and analytical platforms—introduce heterogeneity that limits reproducibility and therefore undermines potential clinical impact of VOC testing.

    This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and does not constitute a contract or medical advice; it may be updated and is subject to change. Providers should consult applicable plan documents and payer guidance for definitive coverage determinations.

    Because available studies do not demonstrate established clinical effectiveness for the listed uses, analysis of volatile organic compounds for those indications is considered not medically necessary and is not supported for routine clinical coverage under this policy.

    For pediatric respiratory diseases specifically, the policy states that exhaled VOC analysis and exhaled breath condensate biomarkers remain investigational; current evidence is insufficient to support clinical diagnostic or monitoring use in children.

    The policy characterizes the overall evidence base for VOC assays as preliminary and heterogeneous: many studies are small, observational, and vary in sampling media and analytic technique, which limits interpretation of reported diagnostic performance and precludes adoption as standalone clinical tests.

    The document advises against clinical implementation of VOC assays that lack external validation, standardized methods, and prospective outcome data. Clinical use should be restricted to validated tests and well‑designed prospective studies until reproducibility and clinical utility are demonstrated.

    Heterogeneity in study design, modest overall study quality, and absence of multicenter validation limit the current utility of VOC‑based tests for screening or diagnosis (for example, colorectal cancer, COVID‑19, and tuberculosis). The policy underscores the need for standardized sampling, consistent analytic strategies, and external validation before routine clinical adoption.

    Covered or Investigational Indications

    None identified as covered

    None identified as covered in this portion of the policy.

    Covered indications: No VOC-based tests or indications are identified as covered in this portion of the policy; although devices such as the OMA-UTI received FDA 510(k) clearance as an aid, clinical outcome evidence of effectiveness is inadequate to support routine coverage.

    Investigational detection or differentiation of disease states

    Investigational disease detection/differentiation: Use of VOC analysis to detect or differentiate disease states such as pediatric inflammatory bowel disease (breath VOCs, AUC up to 0.96 in a pilot study), pancreatic cancer from bile headspace VOCs (single-study model AUC 0.85; sensitivity 83.3%, specificity 81.9%), alcoholic hepatitis (TAP breath score with sensitivity 90% and specificity 80%), prediction of necrotizing enterocolitis (fecal eNose profiles discriminated cases days before clinical onset), and other GI/inflammatory conditions is investigational and limited to research or validation settings pending external validation and standardization.

    Most data are pilot or observational; external validation needed.

    Investigational/diagnostic research use for various cancers

    Investigational/diagnostic cancer applications: VOC analysis for detection or discrimination of cancers (hepatobiliary, pancreatic, renal, gastric, lung, prostate, gastrointestinal, bladder, leukemia/lymphoma) has shown promising discriminatory profiles in multiple small studies and systematic reviews, but methodological heterogeneity, small study sizes, and limited external validation make these applications investigational and appropriate only in research settings until validated prospectively.

    Investigation of COPD phenotypes and potential diagnostic biomarkers

    COPD phenotyping and biomarkers: Investigation of COPD phenotypes and potential diagnostic VOC biomarkers (studies using GC-MS, GC-IMS, GC-APCI-MS) has identified candidate VOCs and prototypes, but reproducibility and longitudinal validation are lacking; use remains investigational.

    Assessment of severe bronchiolitis obliterans syndrome (BOS) post-lung transplant

    BOS post-lung transplant assessment: Breath VOC profiling identified a 4‑VOC combination that discriminated severe bronchiolitis obliterans syndrome (BOS stage 3) with an AUC of 0.87; evidence for detection of earlier BOS stages (1–2) is lacking and clinical use is investigational pending validation.

    Profiling wound VOCs to identify causative bacteria and monitor healing

    Wound VOC profiling: Profiling VOCs from surgical wounds (GC-MS, electronic nose) has identified VOC patterns associated with causative bacteria and may monitor progression toward non-healing wounds; current evidence is limited and investigational pending further validation.

    Exhaled breath profiling for ALS screening/diagnosis (proof-of-concept)

    ALS breath profiling: Exhaled breath profiling using an electronic nose in a small proof-of-concept study discriminated amyotrophic lateral sclerosis (ALS) from controls with an AUC of ~0.795; this application is investigational and requires larger validation studies.

    Research/experimental use for lung cancer, urinary VOCs for various cancers, and CRC screening adjunct to FIT

    Research/experimental cancer and CRC adjunct screening: Research or experimental use of VOC analysis for lung cancer, urinary VOCs for various cancers, and colorectal cancer screening (including adjunctive use with FIT) has yielded promising pooled diagnostic metrics in systematic reviews/meta-analyses, but heterogeneity in methods and lack of multicenter external validation limit clinical adoption; these applications remain investigational.

    Investigation and monitoring of pleural mesothelioma in research settings

    Pleural mesothelioma investigation: Investigation and monitoring of pleural mesothelioma using GC-MS or pattern-recognition technologies has demonstrated high accuracy in small studies but lacks external validation; use should be limited to research settings.

    Investigational screening/detection of colorectal cancer, COVID-19, and tuberculosis — research/validation settings only

    Investigational screening/detection (CRC, COVID-19, TB): Screening or detection of colorectal cancer, COVID-19, and tuberculosis using VOC analysis has shown discrimination potential in studies (including rapid breath tests for COVID-19 and eNose rule-out approaches for TB) but requires multicenter validation, standardized sampling/analysis, and adequate case prevalence before routine clinical use; therefore these uses are investigational.

    Research and reported diagnostic investigations of VOCs for many conditions

    Broad research investigations: Reported diagnostic investigations of VOCs include lung cancer, gastrointestinal diseases, hepatobiliary and pancreatic cancers, urinary tract infections, renal disease, sarcoidosis, asthma, and infectious diseases including COVID-19; these reports provide references but do not establish coverage for routine clinical use.

    Not Covered

    Analysis of volatile organic compounds for detection, diagnosis, screening, or monitoring for the multiple clinical indications listed in this policy is considered not covered because the clinical effectiveness of VOC analysis for these uses has not been established.

    Routine clinical coverage of VOC‑based tests is not supported by the policy due to lack of standardization in collection and analysis methods and absence of sufficient external validation; many tests remain research tools rather than validated clinical assays.

    The policy indicates that VOC profiles have not been established as validated, standalone diagnostic tests across reviewed conditions because methodological heterogeneity, small sample sizes, and limited external validation prevent confirmation of clinical validity and utility.

    Methodological heterogeneity and predominance of small studies are repeatedly cited as limitations that restrict clinical adoption of VOC testing; these factors reduce reproducibility and the ability to generalize reported diagnostic metrics.

    Tests that do not employ standardized methods, lack reproducibility, or have not undergone external validation are not supported for routine clinical screening or diagnostic use according to this policy.

    Within the provided excerpts the policy does not enumerate a separate explicit list of specific commercially named tests that are categorically not covered; rather, the document frames noncoverage around indications and lack of validated methods and external validation.

    Coding

    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    A15.0-A19.9Tuberculosis
    B37.0Candidal stomatitis
    C00.0-C96.9Malignant neoplasms
    D00.1Carcinoma in situ of esophagus
    D00.2Carcinoma in situ of stomach
    D05.00-D05.92Carcinoma in situ of breast
    D24.1-D24.9Benign neoplasm of breast
    D48.60-D48.62Neoplasm of uncertain behavior of breast
    D49.3Neoplasm of unspecified behavior of breast
    D86.0-D86.89Sarcoidosis
    1–10 of 38
    1/4
    Urine culture colony count — standard CFU threshold note
    Standard urine culture threshold>= 100,000 CFU/mL is the classical culture-based definition of bacteriuria for a voided specimen; lower counts (e.g., ~100 CFU) may be used for catheterized or aspirated specimens in symptomatic patients.
    Clinical contextUrinalysis demonstrating bacteriuria plus pyuria is considered diagnostic of UTI; culture thresholds support confirmatory testing.
    Reference practiceUse standard urinalysis and culture with CFU thresholds as the established diagnostic approach prior to considering VOC-based devices.

    Provider Actions and Operational Notes

    Denial Risk

    Coverage requires clinical effectiveness evidence

    Coverage is contingent on demonstrated clinical effectiveness. VOC-based tests lacking adequate clinical outcome evidence are considered experimental/investigational and are at risk for denial when submitted for the indications listed in this policy.

    • Tests without robust clinical effectiveness data may be denied.
    • OMA-UTI has FDA 510(k) clearance but clinical efficacy evidence is limited and insufficient to establish routine coverage.
    Prior Authorization

    Validation requirement for clinical adoption

    Prior to routine clinical adoption, VOC-based tests must undergo independent validation with standardized protocols and multicenter studies. Tests should demonstrate reproducible performance (sensitivity, specificity, AUC) across external cohorts before being used for clinical decision-making.

    • Recommend multicenter external validation and protocol standardization.
    • Report validation metrics (AUC, sensitivity, specificity) and whether findings were replicated in independent cohorts.
    Prior Authorization

    Prior authorization

    Prior authorization may be required for VOC-based testing given the lack of standardized algorithms and variable evidence. Where prior authorization is applied, medical necessity must be documented and justified with validated evidence.

    • No specific payer prior authorization rules are stated in the source — check plan-specific PA requirements.
    • When PA is required, include supporting clinical evidence and rationale for testing.
    Prior Authorization

    Prior authorization for VOC-based tests

    Given heterogeneous methods and the absence of standardized test algorithms for many VOC assays, payers may require prior authorization specifically for VOC-based tests until standardized, validated methods are available.

    • Tests using non-standardized sampling/analysis lack consensus algorithms and are higher risk for noncoverage.
    • Programs may require PA to ensure appropriate use and documentation.
    Prior Authorization

    Prior validation required before routine coverage

    Prior validation in representative clinical populations and standardized procedures is required before routine coverage. Small, single-center studies or studies lacking external validation do not meet this requirement.

    • Require external validation and reporting of sample media effects on performance.
    • Multi-center validation and standardized protocols are recommended prior to coverage.
    Denial Risk

    Experimental/Investigational indications trigger denial

    Claims for indications listed as experimental and investigational (see policy list) are likely to be denied because clinical effectiveness has not been established.

    • Examples include detection of bacteriuria, bronchiolitis obliterans syndrome, many cancers, and numerous diagnostic/monitoring uses listed in the policy.
    • OMA-UTI is noted separately with 510(k) clearance but the broader class of VOC tests for listed indications remains investigational.
    Documentation Required

    Standardization and validation required

    Standardization of sample collection, handling, analytic platforms, and reporting is necessary. Without standardized methods (e.g., breath sampling, headspace sampling, adsorption/desorption protocols, GC-MS or SIFT‑MS parameters), results may be unreliable and not generalizable.

    • Document and follow standardized breath/urine/bile sampling protocols.
    • Control for site-specific differences and confounders (eg, smoking, storage conditions).
    Note

    Not specified in this excerpt; no operational triggers provided

    This excerpt does not specify operational billing, authorization triggers, or detailed plan-level procedures; check plan/provider materials for local operational requirements.

    • No explicit payer prior authorization rules provided in this policy excerpt.
    • Administrative links and policy history are present but do not list provider documentation checklists.
    Denial Risk

    Risks tied to insufficient validation

    Insufficient validation introduces risks including false positives/negatives, poor generalizability due to small sample sizes, and uncertain impact on clinical outcomes. These risks may lead to inappropriate clinical decisions and coverage denials.

    • Small studies and lack of external validation increase the risk of unreliable performance.
    • Inadequate reporting of clinical parameters (eg, disease stage) limits interpretation of clinical utility.
    Denial Risk

    Heterogeneous methods risk noncoverage

    Heterogeneous sampling media and analytic methods across studies contribute to inconsistent results and are a common reason for noncoverage until harmonized methodologies and reproducible performance are demonstrated.

    • Sample media (breath, urine, bile) contributes to heterogeneity in performance.
    • Lack of standardized analytic pipelines (fingerprinting vs chemical identification) impedes reproducibility.
    Note

    No explicit authorization or denial triggers present

    No explicit authorization or automatic denial triggers are stated in the provided policy text; operational decisions may depend on plan-specific administrative procedures and prior authorization criteria.

    • Providers should confirm applicable PA requirements with the payer.
    • The policy history and administrative links are available but do not define operational triggers.
    Documentation Required

    Documentation re: FDA 510(k) and evidence

    Although the OMA-UTI device has FDA 510(k) clearance (2001), the policy notes that 510(k) clearance does not require the level of clinical efficacy evidence needed for a PMA; clinical outcome studies are still necessary to establish effectiveness.

    • OMA-UTI reported sensitivity/specificity ~81%/83% versus culture but broader clinical utility remains unproven.
    • 510(k) clearance indicates substantial equivalence to a predicate device, not definitive clinical benefit evidence.
    Documentation Required

    Required study/test documentation

    When submitting studies or test reports, include detailed analytic and validation information: sample medium, collection/handling methods, analytic platform and settings, statistical methods, and validation metrics (AUC, sensitivity, specificity, confidence intervals).

    • Report whether findings were validated in independent cohorts and provide external validation data.
    • Include details on sample storage (eg, sealed containers, freezing, analysis within recommended timeframe) when applicable.
    Documentation Required

    Documentation of sampling and methods

    Document sampling and breath/biologic-specimen methods explicitly: type of sample (breath, urine, bile), collection device, pre-collection conditions (fasting, room air inhalation), adsorption/desorption media, storage conditions, and timing between collection and analysis.

    • For breath: note reservoir or adsorption approach, controlled inhalation/exhalation protocol, and pre-sampling controls (eg, no smoking).
    • For urine/bile: record container sealing, freezing, and time-to-analysis (recommend within 9–12 months for urine when frozen).
    Documentation Required

    Required test documentation: sample handling and analytic details

    Required test documentation should also include handling details (collection method, sealing, freezing), analytic pipeline (fingerprinting vs chemical identification), algorithms used for classification, and whether multicenter standard operating procedures were followed.

    • Specify whether chemical identification or fingerprinting was performed and provide compound identification where available.
    • Include algorithm/feature selection and classifier performance with cross-validation and external validation results.
    Note

    This section contains administrative links and policy history

    This section includes administrative links, policy history, and notices but does not provide a provider checklist for documentation or explicit operational billing guidance. Providers should consult plan portals for those operational details.

    • Administrative links: Review History, Definitions, Clinical Policy Bulletin Notes are referenced.
    • Policy effective date and next review are listed but operational procedures are not detailed in this excerpt.
    Billing Rule

    Use standard diagnostic pathway before VOC testing

    Use established diagnostic pathways (eg, urinalysis and culture with CFU thresholds for UTI) before considering VOC testing as an adjunct. VOC tests should not replace standard diagnostic algorithms until validated evidence supports such changes.

    • For UTI: rely on urinalysis and culture (classical threshold 100,000 CFU/ml for voided specimens) as primary diagnostics.
    • Consider VOC testing only as adjunctive and only when validated and documented appropriately.
    Note

    Combination testing considerations

    Combination testing (eg, FIT plus VOC for colorectal cancer detection) has shown potential to increase detection in some studies, but standardized methods, external validation, and cost-effectiveness analyses are required before routine adoption.

    • Combined FIT‑VOC testing improved CRC detection in pooled analyses but requires prospective validation in real-life screening settings.
    • Assess cost-effectiveness and standardize sample/analysis protocols prior to payer coverage.

    Ordering Requirements

    Note

    Order established diagnostic tests (urinalysis/culture) as standard pathway

    Standard diagnostic tests (urinalysis and culture with classical thresholds such as ≥100,000 CFU/ml for voided specimens) remain the established ordering pathway; VOC testing has not supplanted these standards.

    Note

    No explicit ordering‑clinician restrictions specified

    The policy does not specify restrictions on which clinicians may order VOC tests; no explicit ordering clinician limitations are provided in these excerpts.

    Documentation Required

    Ensure validated sampling methods and documented analytic platforms when ordering

    Ordering clinicians should ensure that sampling methods and analytical platforms are validated and documented in the laboratory’s reports before relying on VOC test results for clinical decision‑making.

    Prior Authorization

    Limit ordering to validated studies or labs with standardized methods

    Limit ordering of VOC testing to validated clinical studies or laboratories that document standardized collection and analytic protocols and external validation; routine clinical ordering is discouraged until such validation exists.

    Documentation Required

    Use defined protocols and reference standards in research/validation studies

    Research and validation studies should follow defined protocols and appropriate reference standards (for example colonoscopy as the reference standard for colorectal cancer screening) when using VOCs in investigational settings.

    Note

    No specified restrictions on who may order VOC tests in these excerpts

    The provided chunks do not specify who may order VOC tests; ordering‑provider qualifications are not described in these excerpts.

    Frequency Limits

    OMA/urine VOC testing — frequency/usage notes
    OMA (Osmetech Microbial Analyser) urine VOC testingOMA is an automated headspace analyzer using a 4-polymer sensor array to detect urinary bacterial VOCs; studied vs culture on 534 samples (Aathithan et al., sensitivity 84%, specificity 88% when bacteriuria defined as 100,000 CFU/mL).
    Device characteristicsAutomated carousel with vial septum sampling, nitrogen humidified headspace flow across sensors, 3-minute sampling and 4-minute wash cycle; computer-captured sensor-resistance changes recorded for pattern analysis.
    Regulatory noteOsmetech OMA-UTI referenced in FDA 510(k) summary (K011043) as a urinary tract infection detector; manufacturer was not required to submit PMA-level outcome evidence.
    fecal VOC profiling by eNose — daily sampling noted in study-specific contexts
    Study sampling frequencyFecal samples were collected daily (up to day 28 of life) in the neonatal NEC eNose study; daily sampling was study-specific to detect preclinical VOC changes.
    Study contextSamples were allocated into time windows (T-5/T-4, T-3/T-2, T-1/T0) to assess discrimination of NEC versus controls and sepsis using eNose profiles.
    Implication for clinical useDaily sampling schedules reported in research protocols do not imply established clinical-frequency rules; use limited to study settings until validated.
    Not specified — frequency limits not specified in provided chunks
    Frequency limitsNot specified in the provided document excerpts.
    Context noteNo test-specific frequency or periodicity rules are stated for this entry in the source chunks.
    Recommended interpretationTreat frequency as undefined for clinical coverage decisions; refer to research protocol when applicable.
    Placeholder key_value for unknown frequency limits (empty chunk indices)
    Frequency limitsNo information available in the supplied excerpts.
    ActionNo operational frequency limit can be derived; consult full policy or source studies for details.
    NoteThis block is a placeholder for missing frequency-limit data.
    Not specified in this excerpt
    Frequency limitsNot specified in this excerpt.
    Evidence noteThe colorectal cancer urinary VOC reviews describe sample handling (sealed containers, immediate freezing, analysis within 9–12 months) but do not set clinical frequency limits.
    Clinical implicationNo routine frequency recommendations; use limited to research/validation contexts until standards exist.
    Not specified — administrative chunk with review dates
    Frequency limitsNot specified in the provided administrative or policy-history excerpts.
    Policy datesLast review 10/03/2023; next review 08/08/2024 — no frequency rules added in these sections.
    RecommendationRefer to study protocols or full policy text for any test-specific frequency guidance.

    Background and Definitions

    Volatile organic compounds (VOCs) are emitted from biological samples such as breath, urine, and other bodily fluids and have been investigated as noninvasive biomarkers for infections, cancer, metabolic and inflammatory diseases. The policy recognizes VOC analysis as an investigational approach in many contexts and describes analytical platforms (for example, electronic nose technologies) that have been explored in research settings but not established for routine clinical use.

    OMA — Osmetech Microbial Analyser definition / reference
    OMA (Osmetech Microbial Analyser) — definitionOsmetech Microbial Analyser (OMA) is an automated headspace VOC analyzer with polymer sensor array for detecting bacterial VOCs in urine; evaluated in clinical studies and referenced in FDA 510(k) documentation.
    Primary study evidenceAathithan et al (2001) compared OMA results with culture on 534 urine samples demonstrating reported sensitivity 84% and specificity 88% at 100,000 CFU/mL bacteriuria threshold.
    Typical use caseDescribed as an aid for UTI detection in research and device-evaluation settings; not established as a replacement for standard urinalysis/culture in routine clinical practice per policy.
    Analytical VOC detection methods (SIFT-MS, SPME-GC-MS, GC-MS)
    SIFT-MS, SPME-GC-MS, GC-MS — analytical methodsSelected-ion flow-tube MS (SIFT-MS), SPME-GC-MS, and gas chromatography–mass spectrometry (GC-MS) are analytical techniques referenced for VOC detection and quantification in breath, bile, blood, and urine across studies.
    Application examplesSIFT-MS used for bile and breath VOC models (pancreatic cancer, NAFLD); SPME-GC-MS/GC-MS used for blood/breath uremic VOCs and broad chemical identification in many cancer and COPD studies.
    Analytic roleGC-MS is frequently cited as the gold-standard identification method; other platforms support rapid or point-of-care pattern detection in study contexts.
    SIFT-MS definition
    SIFT-MS — definitionSelected-ion flow-tube mass spectrometry (SIFT-MS) is an analytical technique used to quantify VOCs in exhaled breath or headspace samples; used in studies of NAFLD and bile VOCs for pancreatic cancer.
    Study examplesApplied in Alkhouri et al (NAFLD breath panels) and Navaneethan et al (bile headspace for pancreatic cancer) to identify discriminant VOCs and build diagnostic models.
    UtilityEnables quantitative VOC profiling for model development and validation in research settings.
    GC-IMS definition
    GC-IMS — definitionGas chromatography–ion mobility spectrometry (GC-IMS) combines chromatographic separation with ion-mobility detection and has been applied to detect VOCs in bile for gallbladder cancer diagnosis in study contexts.
    Study exampleZhang et al (2022) used GC-IMS to analyze bile VOCs and identified a 12-VOC panel distinguishing gallbladder cancer from benign disease (AUC up to 0.972 in small sample).
    InterpretationGC-IMS provides pattern-separation useful for exploratory and diagnostic VOC panels but requires validation in larger cohorts.
    VOC panels/profiles definition
    VOC panels/profiles — definitionPatterns or sets of volatile organic compounds identified from a sample medium (breath, urine, bile, wound exudate, tissue headspace) used collectively as biomarkers rather than single-analyte tests.
    Evidence roleMultiple studies and meta-analyses report pooled sensitivity/specificity for VOC fingerprinting (e.g., urinary VOCs for CRC: pooled sensitivity 84% and specificity 70%; hepatobiliary VOC AUC ~0.86), highlighting panel-based approaches.
    Clinical implicationVOC panels require standardized collection, analytic methods, and external validation before being considered for routine clinical use.
    eNose / electronic nose definition
    eNose / electronic nose — definitionA pattern-recognition sensor technology (electronic nose, eNose) that profiles VOCs to produce a 'breath-print' or sample signature for disease classification using sensor arrays and pattern-recognition algorithms.
    Study examplesPortable devices such as SniffPhone and other eNose platforms have been used in gastric cancer and NEC studies; eNose profiling enabled discrimination in proof-of-concept and validation cohorts.
    LimitationseNose approaches provide pattern recognition rather than chemical identification and require standardized sampling and external validation for clinical adoption.
    GC-MS definition (gold-standard)
    GC-MS — definitionGas chromatography–mass spectrometry (GC-MS) is considered the gold-standard analytical method for VOC identification and quantification in breath, blood, urine, and other sample media.
    Application examplesUsed for detailed chemical characterization in COPD, uremic breath studies, and many cancer VOC investigations to identify and quantify specific VOC species.
    Role in validationGC-MS-based chemical identification underpins fingerprinting and panel validation but is resource-intensive and typically performed in research laboratories.
    Chemical fingerprinting definition
    Chemical fingerprinting — definitionAn analytical approach that compares overall VOC patterns (fingerprints) rather than identifying individual chemical species; used in urinary VOC CRC studies and meta-analyses reporting pooled diagnostic metrics.
    Practical noteFingerprinting methods can improve discriminative performance but depend on standardized sample collection, storage (sealed containers, immediate freezing), and analytic pipelines.
    Evidence examplevan Liere et al (2023) meta-analysis of urinary VOC fingerprinting reported pooled sensitivity 84% and specificity 70% for CRC detection (chemical fingerprinting studies).
    Electronic nose (eNose) definition and ML-based pattern recognition
    eNose (device + ML) — definitionAn electronic nose combines a sensor array with machine-learning pattern-recognition algorithms to detect disease-specific VOC emission patterns in exhaled breath or other matrices; devices used include portable POC sensors like SniffPhone and Aeonose.
    Performance characteristicseNose devices can provide rapid POC classification (examples: SniffPhone discriminated gastric cancer with AUC 93.8% in a study of 274 patients; GC-IMS breath COVID-19 tests completed in ~10 minutes in research reports).
    LimitationThese devices rely on pattern recognition without necessarily identifying chemical species and require multicenter validation and standardized protocols before routine clinical use.
    electronic nose / Osmetech Microbial Analyser references
    eNose / OMA referencesKey references include Aathithan et al (2001) evaluation of the Osmetech Microbial Analyser (OMA) on 534 urine samples and the FDA 510(k) summary for OMA-UTI (K011043).
    Documentation noteThe FDA 510(k) documentation exists for OMA-UTI, but clinical outcome evidence supporting routine clinical adoption is limited per policy discussion.
    Research implicationHistorical device evaluations inform current investigational status; contemporary adoption requires updated validation and outcome studies.

    Research Evidence Highlights

    18studies in hepatobiliary/pancreatic meta-analysis
    2,296patients in hepatobiliary/pancreatic meta-analysis
    AUC 0.86pooled AUC (hepatobiliary/pancreatic)
    84%pooled sensitivity (CRC chemical fingerprinting)
    70%pooled specificity (CRC chemical fingerprinting)
    AUC 0.87pooled AUC (CRC VOC meta-analysis)
    534urine samples (OMA study)
    1,038urine samples (OMA-UTI FDA 510(k) comparison)

    Supporting the policy’s coverage stance, cited reviews and studies report that much of the VOC literature is preliminary, with small, observational, and heterogeneous studies; inadequate reporting of clinical parameters and limited external validation reduce confidence in reported diagnostic performance and highlight the need for standardized prospective studies.

    Revision History

    2005-10-04policy_effective

    Policy became effective.

    2023-10-03last_reviewLatest

    Most recent policy review conducted.

    2024-08-08next_review_scheduled

    Next policy review scheduled.